Health Industry Headlines: Insolvencies, Legal Battles, and Strategic Acquisitions

France's Carmat has declared insolvency and requested receivership, following a failure to secure emergency funds. Trading of its shares has been halted as the Versailles Economic Affairs Court evaluates the situation.

Bayer finds its glyphosate case stalled at the U.S. Supreme Court, with the court asking for the solicitor general's opinion. This move prolongs a decision on whether the case will be heard, as Bayer seeks resolution over litigation related to the weedkiller.

The FDA is set to update ADHD medication labels, warning of weight loss risks in children under six. This revision emphasizes adverse reactions, highlighting necessary precautions for healthcare providers.

The U.S. House Judiciary Committee has issued a subpoena to former Pfizer executive Philip Dormitzer over allegations of delayed COVID-19 vaccine trial results. This investigation seeks to uncover if delays were strategically timed around the 2020 election.

Moderna's flu vaccine has demonstrated superior efficacy compared to GSK's in adults over 50, potentially boosting shares as mRNA technologies gain prominence amidst declining COVID-19 vaccine sales.

In a strategic move, India's Torrent Pharmaceuticals will acquire a controlling stake in JB Chemicals and Pharmaceuticals. The acquisition, valuing JB Pharma at over $3 billion, signifies India's dynamic pharmaceutical market and Torrent's expanding influence.

(With inputs from agencies.)